Learn more

TCR2 THERAPEUTICS INC

Overview
  • Total Patents
    72
  • GoodIP Patent Rank
    20,322
  • Filing trend
    ⇩ 72.0%
About

TCR2 THERAPEUTICS INC has a total of 72 patent applications. It decreased the IP activity by 72.0%. Its first patent ever was published in 2016. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are SAPIENCE THERAPEUTICS INC, BIONTECH CELL & GENE THERAPIES GMBH and LEXIGEN PHARM CORP.

Patent filings per year

Chart showing TCR2 THERAPEUTICS INCs patent filings per year from 1900 to 2020

Focus industries

# Industry
#1 Pharmaceuticals
#2 Biotechnology

Top inventors

# Name Total Patents
#1 Hofmeister Robert 64
#2 Baeuerle Patrick 48
#3 Sieczkiewicz Gregory 34
#4 Getts Daniel 20
#5 Baeuerle Patrick Alexander 16
#6 Ashminova Vania 10
#7 Ding Jian 9
#8 Donaghey Julie 8
#9 Kieffer-Kwon Philippe 8
#10 Lofgren Michael 5

Latest patents

Publication Filing date Title
WO2021050948A1 Compositions and methods for tcr reprogramming using fusion proteins
WO2020219563A1 Compositions and methods for tcr reprogramming using fusion proteins
WO2020198033A1 Compositions and methods for tcr reprogramming using fusion proteins
TW202026006A Compositions and methods for tcr reprogramming using fusion proteins
CA3106559A1 Compositions and methods for tcr reprogramming using target specific fusion proteins
WO2019222275A2 Compositions and methods for tcr reprogramming using inducible fusion proteins
AU2019231792A1 Compositions and methods for TCR reprogramming using fusion proteins
WO2018232020A1 Compositions and methods for tcr reprogramming using fusion proteins
CN110234343A Engineered T cell for treating cancer
EP3544996A2 Compositions and methods for tcr reprogramming using fusion proteins
BR112019007100A2 compositions and methods for reprogramming t-cell receptors using fusion proteins
EP3494138A1 Compositions and methods for tcr reprogramming using fusion proteins
EP3770168A1 Compositions and methods for tcr reprogramming using fusion proteins